Hypermarcas (OTCMKTS:HYPMY) Upgraded to “Strong-Buy” at Jefferies Financial Group

Hypermarcas (OTCMKTS:HYPMY) was upgraded by stock analysts at Jefferies Financial Group to a “strong-buy” rating in a research note issued on Monday,Zacks.com reports.

Separately, Zacks Research raised Hypermarcas to a “hold” rating in a research report on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy”.

Hypermarcas Stock Performance

Shares of OTCMKTS:HYPMY opened at $4.04 on Monday. Hypermarcas has a one year low of $3.71 and a one year high of $5.50. The stock has a market capitalization of $2.84 billion, a price-to-earnings ratio of 8.41 and a beta of 0.71. The company has a 50-day simple moving average of $4.18 and a 200-day simple moving average of $4.39.

Hypermarcas (OTCMKTS:HYPMY) last released its quarterly earnings results on Wednesday, April 29th. The company reported $0.10 earnings per share (EPS) for the quarter. The firm had revenue of $383.13 million for the quarter. Hypermarcas had a return on equity of 14.08% and a net margin of 19.41%. As a group, research analysts forecast that Hypermarcas will post 0.53 EPS for the current fiscal year.

Hypermarcas Company Profile

Hypermarcas SA is a Brazil-based consumer health and pharmaceutical company whose shares trade over the counter in the United States under the symbol HYPMY. Founded in the early 2000s and headquartered in Rio de Janeiro, the company operates as a holding group for a broad portfolio of branded products in the healthcare and personal care sectors.

Through its various subsidiaries, Hypermarcas develops, manufactures and markets prescription and over-the-counter medications, alongside personal care, baby care, home care and nutritional supplement products.